Page 138 - 南京医科大学自然版

第45卷第5期
·724 · 南 京 医 科 大 学 学 报 2025年5月

apeutic agents targeting acute myeloid leukemia with ［42］STEIN E M，GARCIA⁃MANERO G，RIZZIERI D A，et al.
KMT2A rearrangement or NPM1 mutation［J］. Oncol The DOT1L inhibitor pinometostat reduces H3K79 meth⁃
Ther，2024，12（1）：57-72 ylation and has modest clinical activity in adult acute
［32］LANCET J，RAVANDI F，MONTESINOS P，et al. Cova⁃ leukemia［J］. Blood，2018，131（24）：2661-2669
lent menin inhibitor bmf⁃219 in patients with relapsed or ［43］KLAUS C R，IWANOWICZ D，JOHNSTON D，et al.
refractory（R/R）acute leukemia（AL）：preliminary phase DOT1L inhibitor EPZ⁃5676 displays synergistic antiprolif⁃
1 data from the covalent⁃101 study［J］. Blood，2023，142 erative activity in combination with standard of care drugs
（1）：2916 and hypomethylating agents in MLL⁃rearranged leukemia
［33］JABBOUR E，SEARLE E，ABDUL⁃HAY M，et al. A first⁃ cells［J］. J Pharmacol Exp Ther，2014，350（3）：646-656
in⁃human phase 1 study of the menin⁃KMT2A（MLL1） ［44］ DAFFLON C，CRAIG V J，MÉREAU H，et al. Comple⁃
inhibitor JNJ⁃75276617 in adult patients with relapsed/ mentary activities of DOT1L and menin inhibitors in MLL⁃
refractory acute leukemia harboring KMT2A or NPM1 rearranged leukemia［J］. Leukemia，2017，31（6）：1269-
alterations［J］. Blood，2023，142（1）：57 1277
［34］ ZEIDNER J F，YUDA J，WATTS J M，et al. Phase 1 ［45］DINARDO C D，RAUSCH C R，BENTON C，et al. Clini⁃
results：first⁃in⁃human phase 1/2 study of the menin⁃MLL cal experience with the BCL2 ⁃ inhibitor venetoclax in
inhibitor enzomenib（DSP⁃5336）in patients with relapsed combination therapy for relapsed and refractory acute
or refractory acute leukemia［J］. Blood，2024，144（1）： myeloid leukemia and related myeloid malignancies［J］.

213 Am J Hematol，2018，93（3）：401-407
［35］ WANG E S，ISSA G C，ERBA H P，et al. Ziftomenib in ［46］FENG Z Z，YAO Y，ZHOU C，et al. Pharmacological inhi⁃
relapsed or refractory acute myeloid leukaemia（KOMET⁃ bition of LSD1 for the treatment of MLL⁃rearranged leuke⁃
001）：a multicentre，open⁃label，multi⁃cohort，phase 1 mia［J］. J Hematol Oncol，2016，9：24
trial［J］. Lancet Oncol，2024，25（10）：1310-1324 ［47］HOWARD G C，WANG J，et al. Ribosome subunit attri⁃
［36］ZEIDAN A，FATHI A，ISSA G，et al. POSTER：AML⁃516 tion and activation of the p53⁃MDM4 axis dominate the
KOMET ⁃ 007 trial in progress：a phase Ⅰ study of zifto⁃ response of MLL⁃rearranged cancer cells to WDR5 WIN
menib in combination with venetoclax or venetoclax/ site inhibition［J］. eLife，2024，12：RP90683
azacitidine，or standard induction cytarabine/daunorubicin ［48］ ZHAO Z B，WANG L，VOLK A G，et al. Regulation of
（7+3）chemotherapy in combination with ziftomenib，for MLL/COMPASS stability through its proteolytic cleavage
the treatment of patients with acute myeloid leukemia［J］. by taspase1 as a possible approach for clinical therapy of
Clin Lymphoma Myeloma Leuk，2023，23：S171 leukemia［J］. Genes Dev，2019，33（1/2）：61-74
［37］UDDIN M H，ABOUKAMEEL A，SIDDIQUI S H，et al. ［49］DI MAMBRO A，ARROYO⁃BERDUGO Y，FIORETTI T，
The clinical menin inhibitor ziftomenib and the nuclear et al. SET⁃PP2A complex as a new therapeutic target in
export inhibitor selinexor synergistically inhibit the KMT2A（MLL）rearranged AML［J］. Oncogene，2023，42
growth of MLL⁃r AML［J］. Blood，2023，142（S1）：4168 （50）：3670-3683
［38］AUBREY B J，CUTLER J A，BOURGEOIS W，et al. ［50］HARADA T，HESHMATI Y，KALFON J，et al. A distinct
IKAROS and MENIN coordinate therapeutically action⁃ core regulatory module enforces oncogene expression in
able leukemogenic gene expression in MLL⁃r acute myeloid KMT2A⁃rearranged leukemia［J］. Genes Dev，2022，36（5/
leukemia［J］. Nat Cancer，2022，3（5）：595-613 6）：368-389
［39］ARNOLD O，BARBOSA K，DESHPANDE A J，et al. The ［51］PAN F，IWASAKI M，WU W Q，et al. Enhancer remodel⁃
role of DOT1L in normal and malignant hematopoiesis［J］. ing drives MLL oncogene ⁃ dependent transcriptional
Front Cell Dev Biol，2022，10：917125 dysregulation in leukemia stem cells［J］. Blood Adv，
［40］NGUYEN A T，TARANOVA O，HE J，et al. DOT1L，the 2023，7（11）：2504-2519
H3K79 methyltransferase，is required for MLL⁃AF9⁃medi⁃ ［52］ZHU X N，WEI Y S，YANG Q，et al. FBXO22 promotes
ated leukemogenesis［J］. Blood，2011，117（25）：6912- leukemogenesis by targeting BACH1 in MLL⁃rearranged
6922 acute myeloid leukemia［J］. J Hematol Oncol，2023，16
［41］SHUKLA N，WETMORE C，O’BRIEN M M，et al. Final （1）：9
report of phase 1 study of the DOT1L inhibitor，pinometo⁃ ［53］ELDEEB M，OUYANG Y，GUZZI N，et al. A fetal tumor
stat（EPZ⁃5676），in children with relapsed or refractory suppressor axis abrogates MLL ⁃ fusion ⁃ driven acute
MLL⁃r acute leukemia［J］. Blood，2016，128（22）：2780 myeloid leukemia［J］. Cell Rep，2023，42（2）：112099